English
Polski
Español
українська
Thrombophilia testing in patients with recurrent miscarriages or stillbirth
Recorded at the 7th McMaster International Review Course in Internal Medicine (MIRCIM).
2023-03-29
In what situations should patients with no history of thrombosis be tested for thrombophilia? Should the testing be performed in women planning hormonal contraception or menopausal hormone therapy?
Should homocysteine and MTHFR polymorphism testing be performed in patients with suspected thrombophilia?
In what situations should we perform additional testing for thrombophilia in patients without antiphospholipid syndrome and without any of the 5 basic congenital thrombophilias? What tests to order? Should they include the activity of coagulation factors VIII, IX, and X, and evaluation of the fibrinolytic system (TAFI, plasminogen, PAI-1 activity)?
Is an unexplained increase in the D-dimer level an indication to test for thrombophilia? Is it an indication to introduce antithrombotic prophylaxis?
If you were to name the 3 most important recent advances in hematology that are relevant for everyday practice, what would they be?
Dr Mark Crowther from McMaster University shares his views on the 3 most important recent advances in the management of nonmalignant blood diseases.
What is your management of secondary thrombocytosis?
Do you perform cytogenetic tests in every patient with a myeloproliferative neoplasm (MPN)?
